Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study
Recommended Citation
Veljovich DS, Rothe M, Mangat PK, et al. Palbociclib in patients (pts) with ovarian cancer (OC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. Journal of Clinical Oncology. 2025;43(16_suppl):e17660-e17660. doi:10.1200/JCO.2025.43.16_suppl.e17660
Type
Abstract